Skip to product content

ACTIVE PHARMACEUTICAL INGREDIENT

Omeprazole API

Research Omeprazole API through FDA DMF and China CDE records. Compare reported holders, registration numbers and status definitions, then subscribe to search and export complete available data.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

This profile covers racemic Omeprazole in its free form, CAS 73590-58-6. Sodium and magnesium salts, Esomeprazole, finished dosage forms, pellets and intermediates are excluded. A reported name does not verify the composition, crystalline form or specification of a supplied batch.

Omeprazole registration data overview

This overview includes 41 FDA API DMF records and 18 CDE API registrations for Omeprazole (CAS 73590-58-6), selected by reported substance name. FDA and CDE status counts follow each registry’s own definitions.

0 documented company-name correspondences

The registries have different snapshot dates. Record counts do not represent qualified or available suppliers. Omeprazole subjects are selected by reported name, not by an independently verified CAS assignment for every filing. A lack of documented company-name correspondences does not establish that no companies appear in both registries.

Personal API data subscription

$19.00 per month

$149.00 per year

Billed $149.00 every year

This profile: 41 FDA DMF records, 18 CDE registrations and 0 company-name correspondences.

Subscription benefits and CSV samples
  • Complete available registry records
  • Search and status filters
  • Documented company-name correspondences
  • CSV exports with sources

One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.

Reported companies in Omeprazole registry records

Start an Omeprazole supplier search with the reported names in each market. No cross-registry company-name correspondences are documented for this profile. Similar names, translations and membership of the same corporate group do not prove an identical legal entity or manufacturing site.

Free previewShowing 0 sample records of 0.

0 company-name correspondences

No exact company-name correspondences are documented for these snapshots.

Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.

Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.

US REGULATORY RECORDS

Omeprazole FDA Drug Master Files

Compare Omeprazole holder names, original subjects, submission dates and activity status. Sieved, process-qualified and Form B subjects remain distinct records; those descriptions do not verify the specification of a supplied batch.

41 API DMF records · 31 distinct reported holder names

28Active (A)

13Inactive (I)

A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.

Free previewShowing 3 sample records of 41.

  • ESTEVE QUIMICA SADMF number 11017Inactive (I)Record details
    DMF number
    11017
    Activity status
    Inactive (I)
    DMF type
    II
    Initial submission
    1994-08-02
    Reported holder
    ESTEVE QUIMICA SA
    Reported subject
    OMEPRAZOLE
  • UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)DMF number 11551Inactive (I)Record details
    DMF number
    11551
    Activity status
    Inactive (I)
    DMF type
    II
    Initial submission
    1995-06-09
    Reported holder
    UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)
    Reported subject
    OMEPRAZOLE
  • ESTEVE QUIMICA SADMF number 11794Active (A)Record details
    DMF number
    11794
    Activity status
    Active (A)
    DMF type
    II
    Initial submission
    1995-12-21
    Reported holder
    ESTEVE QUIMICA SA
    Reported subject
    OMEPRAZOLE

Free preview

More records available with a subscription: 38.

Inclusion criteria
  • Includes 41 Type II Omeprazole API records: unqualified, USP, active drug substance, non-sterile drug substance, sieved, PROCESS-II and Form B subjects. Form B is retained as a crystalline-form descriptor, not a separate product identity.
  • Excludes magnesium salts (DMFs 12726, 14649, 17706, 19367, 21100, 21521, 22970, 24982, 25227, 27190, 27734, 30335, 31829, 35390, 38585, 38882 and 39812) and sodium salts (20169, 29981 and 33402). Esomeprazole subjects are excluded as a separate enantiomeric identity.
  • Excludes capsules (DMF 4863), magnesium MUPS tablets (12694), pellets (18334, 18992 and 27411), the chloro compound (29005) and sulphide (38588). These related subjects are not treated as free-form API records.
  • The three Form B records are DMFs 19713, 21793 and 25712. No crystalline-form assignment is inferred for unqualified Omeprazole subjects. Original holder and subject spelling, whitespace and individual DMF numbers are preserved; Excel submission dates are converted to ISO dates. Multiple records may report the same holder.

CHINA REGULATORY RECORDS

Omeprazole NMPA CDE registrations

Compare Omeprazole registrations by number, reported company, product origin and Chinese review status. The table preserves original Chinese substance names and company fields for verification against the official registry.

18 name-selected API registration records

13Approved or qualifying prior approval (A)

5Technical review not passed or unlinked (I)

CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.

Free previewShowing 3 sample records of 18.

  • 湖南九典宏阳制药有限公司Registration number Y20170002344Approved or qualifying prior approval (A)Record details
    Registration number
    Y20170002344
    Reported substance name
    奥美拉唑
    Reported company names
    湖南九典宏阳制药有限公司
    Reported company addresses
    湖南省望城经济技术开发区铜官循环经济工业基地
    Reported product origin
    Domestic (国产)
    Reported packaging
    Not provided by source
    Reported specification
    Not provided by source
    Record updated
    2025-09-30
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2030-09-08
    Source remarks
    CYHT1600564
  • 汕头经济特区鮀滨制药厂Registration number Y20190007714Approved or qualifying prior approval (A)Record details
    Registration number
    Y20190007714
    Reported substance name
    奥美拉唑
    Reported company names
    汕头经济特区鮀滨制药厂
    Reported company addresses
    汕头市韶山路151号
    Reported product origin
    Domestic (国产)
    Reported packaging
    每包1.0kg;25kg/包;25kg/包
    Reported specification
    Not provided by source
    Record updated
    2025-12-10
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2029-11-29
    Source remarks
    国药准字H10980202
  • 常州四药制药有限公司Registration number Y20190008010Approved or qualifying prior approval (A)Record details
    Registration number
    Y20190008010
    Reported substance name
    奥美拉唑
    Reported company names
    常州四药制药有限公司
    Reported company addresses
    江苏省常州市中吴大道567号
    Reported product origin
    Domestic (国产)
    Reported packaging
    5kg/听×2听/箱;25kg/桶
    Reported specification
    Not provided by source
    Record updated
    2025-07-23
    Joint review status
    Approved or qualifying prior approval (A)
    Reported validity date
    2030-07-21
    Source remarks
    国药准字H10950006

Free preview

More records available with a subscription: 15.

Inclusion criteria
  • Includes 18 registrations whose reported substance name is exactly 奥美拉唑. The name-based selection does not independently confirm CAS 73590-58-6, crystalline form or a particular manufacturer specification for each entry.
  • Excludes 22 registrations named 奥美拉唑钠 and 4 named 奥美拉唑镁 as different salt forms. Names beginning 艾司奥美拉唑 are excluded as a different enantiomeric identity. No related salt or enantiomer is treated as an Omeprazole synonym.
  • All eleven source columns and original row order are retained. Blank fields remain blank and are displayed as Not provided by source. Semicolon-separated names and addresses, repeated parties, dates and approval references are preserved without inferring roles or current validity.

Omeprazole chemical identity

Omeprazole is a proton pump inhibitor. ChEBI defines it as a racemate containing equal amounts of the R and S enantiomers, with CAS 73590-58-6. This profile identifies the free form. Esomeprazole is the S enantiomer; sodium and magnesium salts are separate chemical forms. The registry lists do not individually verify these chemical identifiers for every entry.

CAS number
73590-58-6
ChEBI: Omeprazole racemate

Reference identity of the racemic free form; not a CAS assignment independently verified for each registration.

ChEBI identifier
CHEBI:7772
ChEBI: Omeprazole racemate
KEGG Drug identifier
D00455
KEGG Drug: Omeprazole

Omeprazole chemical properties

Use these molecular properties when checking the free-form identity. Omeprazole salts have different compositions, and an enantiomer can share the same formula and mass without being the same substance. Confirm chemical form, crystalline form, assay basis and specification with the manufacturer; identifiers alone do not establish interchangeability.

Molecular formula
C17H19N3O3S
KEGG Drug: Omeprazole
Molecular weight
345.42 g/mol
KEGG Drug: Omeprazole

Reference molecular weight of the free form; not a batch assay or purity result.

Exact mass
345.1147 Da
KEGG Drug: Omeprazole

Chemical-form and regulatory resources

Check Omeprazole identity, structural information and registration scope in these original references.

Omeprazole API sourcing questions

What chemical identity does this Omeprazole page cover?

This profile covers Omeprazole, CAS 73590-58-6, in its racemic free form. Its molecular formula is C17H19N3O3S and reference molecular weight is 345.42 g/mol. Registration tables are selected by reported substance name; the source lists do not independently establish CAS identity, crystalline form or batch specifications for every record.

Is Omeprazole the same as Esomeprazole or the sodium and magnesium salts?

No. Omeprazole is a racemate of the R and S enantiomers; Esomeprazole identifies the S enantiomer. Sodium and magnesium salts are distinct chemical forms. Their registrations are excluded from this free-form profile. Do not use a shared name fragment, molecular mass or therapeutic category as evidence that materials are interchangeable.

Which FDA Omeprazole records are included?

The FDA snapshot includes 41 Type II Omeprazole API records with unqualified, USP, active drug substance, non-sterile drug substance, sieved, process-qualified or Form B subjects. The original qualifiers remain visible. Type II also covers intermediates and drug products, so type alone is insufficient to identify an API filing.

Why are Form B subjects included but pellets excluded?

Form B describes a crystalline form of Omeprazole in the published application US20100183710A1. The three Form B subjects are retained with their exact wording; this does not verify a particular batch’s solid-state properties. Pellets, capsules and tablets describe formulated materials or dosage forms and are outside this API profile. The chloro compound and sulphide subjects are also excluded as related intermediate candidates.

Does an active Omeprazole DMF mean the supplier is FDA approved?

No. FDA A and I indicate active and inactive DMFs. FDA states that DMFs are neither approved nor disapproved and reviews their technical contents with applications that reference them. An Omeprazole DMF listing does not prove manufacturing-site qualification, a right to reference a dossier, current supply or suitability for a specific application.

Which CDE registrations belong to this Omeprazole profile?

The CDE selection contains 18 records named exactly 奥美拉唑. Registrations for 奥美拉唑钠 and 奥美拉唑镁 are separate salt forms; 艾司奥美拉唑 entries are excluded as a different enantiomeric identity. All eleven original columns are retained, including blank values, multiple company names, addresses, packaging, dates and approval references.

What do the CDE A and I identifiers mean?

For Omeprazole registrations, CDE A and I describe Chinese review status independently of FDA activity. A can follow review with an approved formulation, transfer of qualifying prior approvals or an independent API review. I identifies material that has not passed technical review or has not been linked to a formulation registration. Check the current official entry before relying on its status.

How should I compare companies before sourcing Omeprazole API?

Use the registry number to locate the official entry, then ask the company to confirm its legal identity, manufacturing site, chemical and crystalline form, specification and relevant regulatory documentation. Omeprazole supplier qualification also requires a separate quality assessment. A CDE company field may name multiple parties; their order does not establish their roles or a match to an FDA holder.

What Omeprazole data can I preview and export?

Review free Omeprazole samples and download their sample CSV files before subscribing. An active personal subscription provides the complete available records for this profile, with search, status filters and CSV exports. It does not include quotations, supplier qualification or live registry monitoring. Snapshot dates remain visible so you can distinguish the records from a current official lookup.

ChEBI: Omeprazole racemateKEGG Drug: OmeprazoleChEBI: Esomeprazole enantiomer identityFDA DMF list: Q2 2026 snapshotNMPA CDE API registryFDA: Types of Drug Master FilesOmeprazole Form B: published patent applicationFDA: Drug Master FilesChina API registration status explained

Data sources

Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.

ChEBI: Omeprazole racemate

Open source reference

EMBL-EBI

Chemical definition, racemic identity and CAS number of the Omeprazole free form.

View citation evidence

“A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.”

EMBL-EBI

ChEBI definition of CHEBI:7772; the entry also reports CAS 73590-58-6.

KEGG Drug: Omeprazole

Open source reference

KEGG

Molecular formula, molecular weight, exact mass, structure and drug classification for the free form.

View citation evidence

“C17H19N3O3S”

KEGG

Molecular formula reported in KEGG Drug entry D00455; the same entry reports molecular weight 345.42 and exact mass 345.1147.

ChEBI: Esomeprazole enantiomer identity

Open source reference

EMBL-EBI

Defines Esomeprazole by its S configuration and distinguishes it from the Omeprazole racemate.

View citation evidence

“(S)-omeprazole”

EMBL-EBI

Synonym in ChEBI CHEBI:50275; the definition specifies S configuration at the sulfur atom.

Omeprazole Form B: published patent application

Open source reference

U.S. patent application US20100183710A1

The published application describes crystalline Form B of Omeprazole. It supports interpreting the Form B qualifier, not any listed holder’s batch characteristics, patent rights or freedom to operate.

View citation evidence

“crystalline Form B of omeprazole”

U.S. patent application US20100183710A1

Wording in the published application’s summary of the invention, reproduced by Google Patents.

FDA DMF list: Q2 2026 snapshot

Open source reference

U.S. Food and Drug Administration

The records displayed here use the second-quarter snapshot, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.

View citation evidence

“A=active ; I=inactive”

U.S. Food and Drug Administration

FDA activity-status legend; the snapshot date applies to the records shown here.

FDA: Drug Master Files

Open source reference

U.S. Food and Drug Administration

FDA explains how DMFs support applications that reference their technical contents.

View citation evidence

“Are neither approved nor disapproved.”

U.S. Food and Drug Administration

FDA statement about DMFs; active status is not product approval.

FDA: Types of Drug Master Files

Open source reference

U.S. Food and Drug Administration

Type II covers drug substances, intermediates, preparation materials and drug products; a subject-level screen is needed to select API records.

View citation evidence

“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”

U.S. Food and Drug Administration

FDA definition of Type II; the category is broader than API-only filings.

NMPA CDE API registry

Open source reference

Center for Drug Evaluation, National Medical Products Administration

The October 5, 2026 snapshot contains the reported names, company fields and registration information used here.

View citation evidence

“奥美拉唑”

Center for Drug Evaluation, National Medical Products Administration

Exact reported substance name selected from the supplied CDE snapshot; salt and enantiomer registrations are excluded.

China API registration status explained

Open source reference

Liaoning Medical Products Administration

Official explanation of the A and I identifiers, including the different routes by which a record can receive A status.

View citation evidence

“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”

Liaoning Medical Products Administration

The regulator explains I as material that has not passed technical review or has not been linked to a formulation registration.

Continue your Omeprazole API research

Compare Omeprazole registry names, statuses and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.

Complete data requires an active subscription. Already subscribed? Sign in to access your data.

Report a data issue

Report an Omeprazole data issue with the page address, registry number and supporting official source. APIRFQ support handles data corrections; contact the relevant company separately about material specifications or supply.

Contact data support